The DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Open accessAbstract
This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic "hits". The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–203 of 203
When the journey from obesity to cirrhosis takes an early start
Ratziu, V., & Marchesini, G. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.021 · Cited by 14
Self-citationIs Cholangiocarcinoma Another Complication of Insulin Resistance: A Report of Three Cases
Michelini, E., Lonardo, A., Ballestri, S., Costantini, M., Caporali, C., Bonati, M. E., Bertolotti, M., Iori, R., & Loria, P. (2007) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2006.0018 · Cited by 13
Self-citationMiddleton, J. P., Wiener, R. C., Barnes, B. H., Gurka, M. J., & DeBoer, M. D. (2014) · Clinical Pediatrics · doi:10.1177/0009922813520072 · Cited by 11
Cited by
Sex and gender: modifiers of health, disease, and medicine
Mauvais-Jarvis, F., Bairey Merz, N., Barnes, P. J., Brinton, R. D., Carrero, J.-J., DeMeo, D. L., De Vries, G. J., Epperson, C. N., Govindan, R., Klein, S. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31561-0 · Cited by 2,001
Self-citationObesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
Gart, E., Souto Lima, E., Schuren, F., De Ruiter, C. G. F., Attema, J., Verschuren, L., Keijer, J., Salic, K., Morrison, M. C., & Kleemann, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010001 · Cited by 1,093
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Lonardo, A., Nascimbeni, F., Mantovani, A., & Targher, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.021 · Cited by 736
Self-citationBallestri, S., Nascimbeni, F., Baldelli, E., Marrazzo, A., Romagnoli, D., & Lonardo, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0556-1 · Cited by 545
Self-citation
Metadata
- Authors
- Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., Miele, L., Morisco, F., Petta, S., Piscaglia, F., Svegliati-Baroni, G., Valenti, L., & Bellentani, S.
- Venue
- Digestive and Liver Disease
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 49
- Issue
- 5
- Pages
- 471-483
- ISSN
- 1590-8658 (ISSN-L)
- OpenAlex
- W2582145734
- Cited by
- 306
- References
- 203
- FWCI
- 31.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.